open access

Vol 58, No 5 (2007)
Original papers
Published online: 2007-10-16
Submitted: 2013-02-15
Get Citation

The importance of bisoprolol in prevention of heart left ventricular hypertrophy in patients with long term L-thyroxin suppressive therapy, after the operation of differentiated thyroid carcinoma

Gabriela Matuszewska, Bogdan Marek, Dariusz Kajdaniuk, Brygida Przywara-Chowaniec, Jerzy Jarząb, Barbara Jarząb
Endokrynologia Polska 2007;58(5):384-396.

open access

Vol 58, No 5 (2007)
Original papers
Published online: 2007-10-16
Submitted: 2013-02-15

Abstract


Introduction: Patients with differentiated thyroid carcinoma have to undergo radical surgical treatment, which includes total thyreoidectomy, radioiodine therapy and a life-time supressive therapy with L-thyroxine. The aim of this study was a prospective evaluation of left ventricular hypertrophy during L supressive-thyroxine treatment in patients treated for differentiated thyroid carcinoma.
Material and methods: The examined group comprised 50 patients with differentiated thyroid carcinoma, treated by total thyroidectomy and 131I therapy. Echocardiographic measurements were needed for estimation of left ventricular mass and its index, according to recommendations of American Echocardiography Society.
Results: During two-years long supressive therapy we observed a significant rise in left ventricular mass. In woman group left ventricular mass was increased from 168 &#177; 39 g to 204 &#177; 45 g (p < 0.001) and in men from 205 &#177; 60 to 320 &#177; 21 g. Likewise, left ventricular mass index was increased in women group from 96 &#177; 18 g/m&#178; to 116 &#177; 25 g/m&#178; (p < 0.001) and in men group from 107 &#177; 37 g/m&#178; to 158 &#177; 28 g/m&#178;. Simultaneous treatment with bisoprolol caused a regression of left myocardial hypertrophy. Already after 6 months of simultaneous treatment with L-tyroxin and bisoprolol, for left ventricular mass was reduced to normal: in woman 165 &#177; 35 g, and in men to 178 &#177; 38 g. Analogous results were obtained left ventricular mass index. After 6 months it was reduced to 94 &#177; 12 g/m&#178; in woman and in men to 132 &#177; 32 g/m&#178;.
Conclusions:
1. In differentiated thyroid cancer patients, treated postoperatively with L-thyroxine supressive therapy, left ventricular hypertrophy is observed already during the first year of supressive therapy and progresses during the next year of treatment.
2 Addition of a beta-adrenergic antagonist to supressive doses of L-thyroxine causes a regression of left ventricular hypertrophy, thus, beta-adrenergic antagonists should be administred in this group of patients.
(Pol J Endocrinol 2007; 58 (5): 384-396)

Abstract


Introduction: Patients with differentiated thyroid carcinoma have to undergo radical surgical treatment, which includes total thyreoidectomy, radioiodine therapy and a life-time supressive therapy with L-thyroxine. The aim of this study was a prospective evaluation of left ventricular hypertrophy during L supressive-thyroxine treatment in patients treated for differentiated thyroid carcinoma.
Material and methods: The examined group comprised 50 patients with differentiated thyroid carcinoma, treated by total thyroidectomy and 131I therapy. Echocardiographic measurements were needed for estimation of left ventricular mass and its index, according to recommendations of American Echocardiography Society.
Results: During two-years long supressive therapy we observed a significant rise in left ventricular mass. In woman group left ventricular mass was increased from 168 &#177; 39 g to 204 &#177; 45 g (p < 0.001) and in men from 205 &#177; 60 to 320 &#177; 21 g. Likewise, left ventricular mass index was increased in women group from 96 &#177; 18 g/m&#178; to 116 &#177; 25 g/m&#178; (p < 0.001) and in men group from 107 &#177; 37 g/m&#178; to 158 &#177; 28 g/m&#178;. Simultaneous treatment with bisoprolol caused a regression of left myocardial hypertrophy. Already after 6 months of simultaneous treatment with L-tyroxin and bisoprolol, for left ventricular mass was reduced to normal: in woman 165 &#177; 35 g, and in men to 178 &#177; 38 g. Analogous results were obtained left ventricular mass index. After 6 months it was reduced to 94 &#177; 12 g/m&#178; in woman and in men to 132 &#177; 32 g/m&#178;.
Conclusions:
1. In differentiated thyroid cancer patients, treated postoperatively with L-thyroxine supressive therapy, left ventricular hypertrophy is observed already during the first year of supressive therapy and progresses during the next year of treatment.
2 Addition of a beta-adrenergic antagonist to supressive doses of L-thyroxine causes a regression of left ventricular hypertrophy, thus, beta-adrenergic antagonists should be administred in this group of patients.
(Pol J Endocrinol 2007; 58 (5): 384-396)
Get Citation

Keywords

differentiated thyroid carcinoma; L-thyroxin therapy; left ventricular hypertrophy; bisoprolol

About this article
Title

The importance of bisoprolol in prevention of heart left ventricular hypertrophy in patients with long term L-thyroxin suppressive therapy, after the operation of differentiated thyroid carcinoma

Journal

Endokrynologia Polska

Issue

Vol 58, No 5 (2007)

Pages

384-396

Published online

2007-10-16

Bibliographic record

Endokrynologia Polska 2007;58(5):384-396.

Keywords

differentiated thyroid carcinoma
L-thyroxin therapy
left ventricular hypertrophy
bisoprolol

Authors

Gabriela Matuszewska
Bogdan Marek
Dariusz Kajdaniuk
Brygida Przywara-Chowaniec
Jerzy Jarząb
Barbara Jarząb

Important: This website uses cookies.tanya dokter More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Via MedicaWydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl